IN THE CLAIMS:

1. An aqueous pharmaceutical formulation suitable for intravenous injection comprising:

an anti-ulcerative compound having the following formula:



wherein R^1 and R^2 are independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, halogenated lower alkyl, lower alkoxycarbonyl, a carboxyl group, and halogen;

X is a member selected from the group consisting of –O–, –S– or



where R^3 is a member selected from the group consisting of hydrogen, lower alkyl, phenyl, benzyl, and lower alkoxycarbonyl; and

Z is selected from the group consisting of:

(1) a group of the formula:

$-O(CH_2)_p-O-R^4$

where p is an integer of 1 to 3 and R^4 is a hydrogen atom or a lower alkyl, aryl or aralkyl group;

(2) a group of the general formula:

$-O(CH_2)_q-R^5$

where q is an integer of 1 to 3 and R^5 is a halogen atom or an alkoxycarbonyl, aryl or heteroaryl group;

(3) a group of the general formula:

$-O(CH_2)_r-O(CH_2)_s-R^6$

where r and s each independently are an integer of 1 to 5 and R^6 is a hydrogen atom or a lower alkyl group;

(4) a group of the formula:  ;

(5) a group of the formula:  ;

(6) a group of the formula:  ;

(7) a group of the general formula:  ;

where t is an integer of 0 to 2 and A is a lower alkyl, alkoxycarbonylmethyl, pyridyl or furyl

group, or a group of the general formula:  ,

where P is selected from the group consisting of: –NH–, –O– or –S–.or a group of the general formula:



wherein R^7 is hydrogen or lower alkyl and w is from 0 to 3;

(8) a group of the general formula:  where R^8 is an

acetoxy or lower alkyl group; and

(9) a group of the general formula: $-OR^9$

where R^9 is a hydrogen atom or a lower alkyl or aryl group;

n is an integer of 0 to 2; m is an integer of 2 to 10, and

J and K are independently hydrogen or lower alkyl, with the proviso that when Z is a group falling under the above category (9), R^9 is a lower alkyl group and m stands for an integer of 3 to 10, and pharmaceutically acceptable salts thereof; and

glycine, in a pharmaceutically acceptable carrier.

2. An aqueous pharmaceutical formulation of claim 1 suitable for intravenous injection comprising:

an anti-ulcerative compound having the following formula:



wherein R^1 and R^2 are independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, halogenated lower alkyl, lower alkoxycarbonyl, a carboxyl group, and halogen;

wherein R^9 is selected from the group consisting of hydrogen, lower alkyl, and aryl;

wherein J is selected from the group consisting of hydrogen or lower alkyl;

wherein m is an integer from 2 to 10;

and pharmaceutically acceptable salts thereof;

glycine, sodium hydroxide; and

a tonicity agent.

3. An aqueous pharmaceutical formulation of claim 1 suitable for intravenous injection comprising:

an anti-ulcerative compound having the following formula:



wherein R^1 and R^2 are independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, halogenated lower alkyl, lower alkoxycarbonyl, a carboxyl group, and halogen;

wherein R^4 is selected from the group consisting of hydrogen, lower alkyl, aryl, and aralkyl;

wherein J is selected from the group consisting of hydrogen or lower alkyl;

wherein m is an integer from 2 to 10;

wherein p is an integer from 1 to 3;

and pharmaceutically acceptable salts thereof;

glycine, sodium hydroxide; and

a tonicity agent.

Sub C2

4. The aqueous pharmaceutical formulation suitable for intravenous injection of claim 1 wherein said tonicity agent is selected from the group consisting of sodium chloride, glycerin, mannitol, sucrose, lactose, and dextrose.

5. The aqueous pharmaceutical formulation suitable for intravenous injection of claim 2 wherein said tonicity agent is selected from the group consisting of sodium chloride and dextrose.

6. The aqueous pharmaceutical formulation suitable for intravenous injection of claim 3 wherein said tonicity agent is selected from the group consisting of sodium chloride and dextrose.

Sub C3

7. The aqueous pharmaceutical formulation suitable for intravenous injection of claim 1 wherein said compound is



8. The aqueous pharmaceutical formulation suitable for intravenous injection of claim 7 wherein said tonicity agent is selected from the group consisting of sodium chloride and dextrose.

9. The aqueous pharmaceutical formulation suitable for intravenous injection of claim 8 wherein said tonicity agent is sodium chloride and said sodium chloride is present in said formulation at a concentration of about 0.9% by weight.

10. The aqueous pharmaceutical formulation suitable for intravenous injection of claim 8 wherein said tonicity agent is dextrose and said dextrose is present in said formulation at a concentration of about 5% by weight.

11. The aqueous pharmaceutical formulation suitable for intravenous injection of claim 1 wherein said formulation has an alkaline pH, and wherein said glycine in said formulation is present at a concentration of between about 1 mM and 300 mM.

12. The aqueous pharmaceutical formulation suitable for intravenous injection of claim 4 wherein said formulation has a pH of between about 9 and about 12, and wherein said glycine in said formulation is present at a concentration of between about 10 mM and 300 mM.

13. The aqueous pharmaceutical formulation suitable for intravenous injection of claim 8 wherein said formulation has a pH of between about 9 and 12, and wherein said glycine in said formulation is present at a concentration of between about 10 mM and 300 mM.

14. A method for stabilizing anti-ulcerative formulations suitable for intravenous injection which comprises:

providing a compound of the formula



wherein R^1 and R^2 are independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, halogenated lower alkyl, lower alkoxycarbonyl, a carboxyl group, and halogen;

X is a member selected from the group consisting of –O–, –S– or  ,

where R^3 is a member selected from the group consisting of hydrogen, lower alkyl, phenyl, benzyl, and lower alkoxycarbonyl; and

Z is selected from the group consisting of:

(1) a group of the formula:

$-O(CH_2)_p-O-R^4$

where p is an integer of 1 to 3 and R^4 is a hydrogen atom or a lower alkyl, aryl or aralkyl group;

(2) a group of the general formula:

$-O(CH_2)_q-R^5$

where q is an integer of 1 to 3 and R^5 is a halogen atom or an alkoxycarbonyl, aryl or heteroaryl group;

(3) a group of the general formula:

$-O(CH_2)_r-O(CH_2)_s-R^6$

where r and s each independently are an integer of 1 to 5 and R^6 is a hydrogen atom or a

lower alkyl group;

(4) a group of the formula:  ;

(5) a group of the formula:  ;

(6) a group of the formula:  ;

(7) a group of the general formula:  ;

where t is an integer of 0 to 2 and A is a lower alkyl, alkoxycarbonylmethyl, pyridyl or furyl group, or a group of the general formula:  ,

where P is selected from the group consisting of: –NH–, –O– or –S– or a group of the general formula:



wherein R^7 is hydrogen or lower alkyl and w is from 0 to 3;

(8) a group of the general formula:  where R^8 is an

acetoxy or lower alkyl group; and

(9) a group of the general formula: $-OR^9$

where R^9 is a hydrogen atom or a lower alkyl or aryl group;

n is an integer of 0 to 2; m is an integer of 2 to 10, and

J and K are independently hydrogen or lower alkyl, with the proviso that when Z is a group falling under the above category (9), R^9 is a lower alkyl group and m stands for an integer of 3 to 10, and pharmaceutically acceptable salts thereof;

providing a solution suitable for intravenous injection which has a pH of between about 10 and 11 and which comprises glycine; and

admixing said compound and said solution until said compound is dissolved in said solution.

15. The method of claim 14 wherein said solution contains a solute selected from the group consisting of dextrose and sodium chloride.

16. The method of claim 14 wherein said glycine is present in said solution at a concentration of between about 10 and about 300 mM.

17. The method of claim 14 wherein said compound is



18. The method of claim 17 wherein said solution contains a solute

selected from the group consisting of dextrose and sodium chloride.

19. The method of claim 18 wherein said glycine is present in said solution at a concentration of between about 10 and about 300 mM.

20. The method of claim 19 wherein said solution contains a solute selected from the group consisting of dextrose and sodium chloride, and wherein said solution is isotonic with blood plasma.

21. The formulation of claim 1, which comprises a tonicity agent.

22. The formulation of claim 1, which comprises sodium hydroxide.

23. The method of claim 11, wherein said alkaline pH is between about 9 and about 12.